Evaxion Biotech A/S: Strategic Financial Moves in 2024 Form 6-K Report

Here are the key insights extracted from the financial report (Form 6-K) of Evaxion Biotech A/S:

1. Company Overview:

• Name: Evaxion Biotech A/S
• Business Sector: Clinical-stage TechBio company focused on developing AI-Immunology™ powered vaccines.
• Headquarters: Dr. Neergaards Vej 5f, DK-2970 Hoersholm, Denmark.

2. Filing Details:

• Filing Type: Form 6-K.
• Commission File Number: 001-39950.
• Date of Report: December 17, 2024.
• Reporting Requirement: The report is submitted pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.

3. Incorporation by Reference:

• This report is incorporated by reference in multiple registration statements including Form S-8 and several Form F-1 filings.

4. Recent Press Release:

• On December 17, 2024, Evaxion Biotech announced its pursuit of an agreement with the European Investment Bank (EIB) to enhance its equity position through the conversion of debt into equity.
• The press release is included as Exhibit 99.1.

5. Signatures:

• The report is signed by Christian Kanstrup, the Chief Executive Officer of Evaxion Biotech A/S.

Summary of Insights:

• Evaxion Biotech is actively engaging in strategic financial maneuvers to bolster its capital through debt conversion, signaling a proactive approach to managing its financial health. The incorporation of this report into various registration statements indicates ongoing compliance with regulatory requirements and a focus on maintaining investor relations.